Pharmaceutical giant Moderna is making headlines again, not just for its strong global vaccine sales, but for a dramatic turn of events with American health regulators. The company recently faced a major hurdle regarding its new flu vaccine, sparking a tense standoff that has finally been resolved.
Earlier this year, the United States Food and Drug Administration (FDA) initially turned down Moderna’s request to review its flu shot. This rejection triggered a public disagreement between the drug maker and the health agency, leaving many observers wondering about the future of the product.
However, the situation took a swift turn just days later when the FDA reversed its decision. The agency has now agreed to fast-track the review process, providing a much-needed boost for Moderna as it seeks to expand its influence in the preventive medicine market.
Health experts are now waiting for the final verdict, which is expected by August 5. If the vaccine receives the green light, it will be ready for rollout just in time for the upcoming flu season, offering a significant new option for patients seeking protection against the virus.
Source: financialpost.com
photo: pexels
